PF-06747143

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePF-06747143
Drug Alias NamePF-06747143
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsApoptosis stimulantsC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A